Maarten J. Deenen

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 333 citations · Full text

Relationship between Single Nucleotide Polymorphisms and Haplotypes in <i>DPYD</i> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Maarten J. Deenen, Jolien Tol, Artur M Burylo et al. · Clinical Cancer Research · 2011 · 183 citations

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

Didier Meulendijks, Linda M. Henricks, Bart Jacobs et al. · British Journal of Cancer · 2017 · 119 citations · Full text

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines

Esther Brandon, Tessa M. Bosch, Maarten J. Deenen et al. · Toxicology and Applied Pharmacology · 2005 · 110 citations

Oncology, Oncogenic Agent, Medicine +10

Toward predicting CYP2D6-mediated variable drug response from <i>CYP2D6</i> gene sequencing data

Maaike van der Lee, William G. Allard, Rolf H. A. M. Vossen et al. · Science Translational Medicine · 2021 · 62 citations